[{"orgOrder":0,"company":"GlycoNex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"GlycoNex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GlycoNex \/ Undisclosed"},{"orgOrder":0,"company":"GlycoNex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"GlycoNex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GlycoNex \/ Undisclosed"},{"orgOrder":0,"company":"GlycoNex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"GlycoNex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GlycoNex \/ Undisclosed"},{"orgOrder":0,"company":"GlycoNex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"GNX102","moa":"Tumor-associated glycan antigen (TAGA)","graph1":"Oncology","graph2":"Phase I","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GlycoNex \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GlycoNex \/ Undisclosed"},{"orgOrder":0,"company":"GlycoNex","sponsor":"Sterling Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"GNX102-ADC","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GlycoNex \/ GlycoNex","highestDevelopmentStatusID":"4","companyTruncated":"GlycoNex \/ GlycoNex"}]